- Home
- BME vs ABUS Comparison
BME vs ABUS Comparison
Compare BME & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BME
- ABUS
- Stock Information
- Founded
- BME 2005
- ABUS N/A
- Country
- BME United States
- ABUS United States
- Employees
- BME N/A
- ABUS N/A
- Industry
- BME Trusts Except Educational Religious and Charitable
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- BME Finance
- ABUS Health Care
- Exchange
- BME Nasdaq
- ABUS Nasdaq
- Market Cap
- BME 525.3M
- ABUS 629.1M
- IPO Year
- BME N/A
- ABUS N/A
- Fundamental
- Price
- BME $39.49
- ABUS $3.20
- Analyst Decision
- BME
- ABUS Strong Buy
- Analyst Count
- BME 0
- ABUS 4
- Target Price
- BME N/A
- ABUS $5.50
- AVG Volume (30 Days)
- BME 34.0K
- ABUS 919.1K
- Earning Date
- BME 01-01-0001
- ABUS 02-27-2025
- Dividend Yield
- BME 6.26%
- ABUS N/A
- EPS Growth
- BME N/A
- ABUS N/A
- EPS
- BME 1.44
- ABUS N/A
- Revenue
- BME N/A
- ABUS $6,742,000.00
- Revenue This Year
- BME N/A
- ABUS N/A
- Revenue Next Year
- BME N/A
- ABUS N/A
- P/E Ratio
- BME $28.37
- ABUS N/A
- Revenue Growth
- BME N/A
- ABUS N/A
- 52 Week Low
- BME $35.53
- ABUS $2.27
- 52 Week High
- BME $43.20
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- BME 59.19
- ABUS 42.47
- Support Level
- BME $38.63
- ABUS $3.16
- Resistance Level
- BME $39.44
- ABUS $3.38
- Average True Range (ATR)
- BME 0.55
- ABUS 0.15
- MACD
- BME 0.19
- ABUS 0.01
- Stochastic Oscillator
- BME 95.11
- ABUS 19.05
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.